Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose and recommended phase 2
dose of PF-03814735 administered orally as single agent in patients with advanced solid
tumors.